Abstract:Abstract Preclinical models (typically ovariectomized rats and genetically altered mice) have underpinned much of what we know about skeletal biology. They have been pivotal for developing therapies for osteoporosis and monogenic skeletal conditions, including osteogenesis imperfecta, achondroplasia, hypophosphatasia, and craniodysplasias. Further therapeutic advances, particularly to improve cortical strength, require improved understanding and more rigorous use and reporting. We describe here how trabecular and cortical bone structure develop, are maintained, and degenerate with aging in mice, rats, and humans, and how cortical bone structure is changed in some preclinical models of endocrine conditions (eg, postmenopausal osteoporosis, chronic kidney disease, hyperparathyroidism, diabetes). We provide examples of preclinical models used to identify and test current therapies for osteoporosis, and discuss common concerns raised when comparing rodent preclinical models to the human skeleton. We focus especially on cortical bone, because it differs between small and larger mammals in its organizational structure. We discuss mechanisms common to mouse and human controlling cortical bone strength and structure, including recent examples revealing genetic contributors to cortical porosity and osteocyte network configurations during growth, maturity, and aging. We conclude with guidelines for clear reporting on mouse models with a goal for better consistency in the use and interpretation of these models.

What problem does this paper attempt to address?

The paper primarily explores preclinical rodent models used to study human skeletal diseases, particularly those related to cortical bone, and attempts to address the following key issues: 1. **Differences in Cortical Bone Structure**: The differences in cortical bone structure between small mammals (such as mice and rats) and large mammals (including humans). Due to the thinner cortical bone and shorter lifespan of small rodents, they cannot form complex cortical bone structures similar to humans (e.g., Haversian systems). Therefore, whether these models are suitable for studying cortical bone strength and related treatments. 2. **Effectiveness of Existing Therapies**: Current treatments for osteoporosis are effective in preventing vertebral fractures but less effective in preventing non-vertebral fractures (such as hip or wrist fractures). The paper explores why existing therapies are insufficient in improving cortical bone strength and suggests that a deeper understanding of the biological mechanisms of cortical bone is needed to develop new treatments. 3. **Genetic Control Mechanisms**: The paper discusses whether the genetic control mechanisms in the development of cortical and trabecular bone are conserved among mice, rats, and humans. By comparing the similarities and differences between species, a better understanding of the regulatory mechanisms of cortical bone strength and structure can be achieved, providing guidance for future research. In summary, the paper aims to find new ways to improve existing treatments by thoroughly analyzing the application of rodent models in the study of osteoporosis and other skeletal diseases, particularly the limitations and advantages in the field of cortical bone.

Preclinical Rodent Models for Human Bone Disease, Including a Focus on Cortical Bone